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Background
Nitrergic nerves and endothelial cells release nitric oxide
(NO) in the corpus cavernosum (CC), a key mediator that
stimulates soluble guanylyl cyclase to increase cGMP lev-
els and cause penile erection. Phosphodiesterase 5
(PDE5) inhibitors, such as sildenafil, prolong NO effects
by inhibiting cGMP breakdown.
Purpose
We aimed to investigate the effects of the novel PDE5
inhibitor lodenafil carbonate (Fig. 1a) on in vitro cavern-
osal relaxation, mean arterial pressure, activity of crude
PDE extracts from human platelets as well as to evaluate
its pharmacokinetic properties.
Methods
In functional studies, cavernosal strips were mounted in
organ baths for isometric force recording, coupled to a
PowerLab 8/SP™ data acquisition system. Rats were surgi-
cally manipulated and telemetry transmitters were
implanted in the abdominal aorta for measurements of
systolic, diastolic and mean arterial blood pressure. For
determination of PDE activity by LC-MS/MS analysis,
lodenafilc arbonate (0.005–1 μM) was preincubated in
the enzymatic mixture for 5 min at room temperature.
Reaction was initiated by the addition of the substrate
cGMP (5 μM) at 35°C for 30 min. Pharmacokinetics was
studied by tandem mass spectrometry (LC-MS/MS) with
positive ion electrospray ionization using multiple reac-
tions monitoring (NMR) method. Blood samples were
collected at 0.02 to 24 h after drug administration by
intravenous (1 mg/kg) and oral (10 mg) routes. The
hydrolysis of lodenafil carbonate (final concentration 10
μM) was also studied in human, dog and rat plasma as
well as in acid solution (100 mM hydrochloric acid).
Results
The cumulative addition (0.001–100 μM) lodenafil car-
bonate to the bathing medium produced concentration-
dependent relaxations in phenylephrine-precontracted
CC with pEC50 values of 6.55 ± 0.02 and 5.97 ± 0.07 in
rabbit and human tissues, respectively (Fig. 1b). The addi-
tion of lodenafil carbonate (0.1 μM) caused significant
leftward shifts in the concentration-response curves to
acetylcholine (0.01–100 μM) in rabbit and human corpus
cavernosum, along with and enhancement of maximal
responses. The addition of lodenafil carbonate signifi-
cantly potentiated both the magnitude and the duration
of electrically-evoked relaxant responses (1–20 Hz) in
human and rabbit penile tissue. Treatment with lodenafil
carbonate (1–10 mg/kg) caused neither dose- nor time-
dependent changes in the mean arterial blood pressure
(123 ± 6 mmHg to 132 ± 7 among the different doses and
times selected for measurements). Lodenafil carbonate
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ing inhibitor concentration, with IC50 value approxi-
mately 2-fold lower than sildenafil at the substrate
concentration used (5 μM) (Fig. 1c). Following a single
i.v. dose of lodenafil carbonate (1 mg/kg) to male Beagle
dogs, the compound exhibited Cmax of 599 ng/ml and
high plasma clearance of 3.24 l/h/kg with a volume of dis-
tribution of 2.73 l/kg. This volume of distribution resulted
in the elimination half-life value of 0.57 h (Fig. 1d).
Plasma concentrations of lodenafil carbonate after a sin-
gle oral dose (10 mg) achieved a Cmax of 11 ng/ml (Fig.
1e). However, the Cmax for lodenafil was 1357 ng/ml and
Tmax was approximately 2 h, reflecting the occurrence of
systemic metabolism. The half-life of lodenafil carbonate
after p.o. administration (2.11 h) was slightly longer than
the equivalent value after i.v. dosing, suggesting that the
rate of absorption limited the overall rate of elimination.
In the study of the stability of lodenafil carbonate (1 μM)
in acid solution, the employment of HPLC and mass spec-
tral analysis of the 2 h incubations revealed the presence
of lodenafil and lodenafil carbonate as the major compo-
nents detected. The retention times obtained for sildena-
fil, lodenafil, lodenafil carbonate and demethylsildenafil
were 4.00, 2.51, 7.43 and 2.04 min, respectively. In
human and dog plasma, a similar qualitatively pattern
was observed, with lodenafil carbonate being detected in
higher levels than lodenafil. No trace of demethylsildena-
fil was detected in both acid and plasma stability assays.
Conclusion
Lodenafil carbonate compound, which concentration-
dependently inhibits cGMP-dependent PDE hydrolytic
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(a) Structure of lodenafil carbonate; (b) Concentration-response curves to lodenafil carbonate (0.001–100 μM) in rabbit 
(closed circles) and human (open circles) CC; (c) Effect of lodenafil carbonate on cyclic GMP hydrolysis; (d, e) Mean plasma 
concentrations of lodenafil carbonate, lodenafil and demethylsildenafil in Beagle dogs after single intravenous (1 mg/kg; top) and 
































ePage 2 of 3
(page number not for citation purposes)
BMC Pharmacology 2007, 7(Suppl 1):P13 http://www.biomedcentral.com/1471-2210/7/S1/P13Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
activity, relaxes human and rabbit cavernosal tissue and
enhance endogenous NO-induced responses. Advances in
treatment of erectile dysfunction seem likely in the imme-
diate future and lodenafil carbonate represents an attrac-
tive agent in that regard, based on the findings provided
in the present investigation.Page 3 of 3
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